Breakthrough bioconvergence platform detects inflammatory events prior to symptoms, partnering with Altesa Biosciences to transform care

Sensifai emerges from stealth with a landmark peer-reviewed study in The Lancet Digital Health, validating its world-first AI platform to detect inflammatory events before symptoms, redefining how and when care begins.

Funding to help company expand its reach across North America and Europe.

Funding Led by Glen Ventures with Significant Support from the Government of Quebec

VC firm to raise dedicated fund in new year separate from government mandate.